Reviva to Participate in the 2025 BIO CEO & Investor Conference
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the 2025 BIO CEO & Investor Conference.
The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will be part of a panel discussion titled 'Tackling Mental Health through New Targets and Endpoints Progress'. The panel is scheduled for Tuesday, February 11, 2025, at 1:00 p.m. ET in New York, NY.
The conference will take place from February 10-11, 2025, and interested parties can register for the event and schedule one-on-one meetings with Reviva's management team.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata focalizzata sullo sviluppo di terapie per malattie del sistema nervoso centrale (CNS), infiammazioni e malattie cardiometaboliche, ha annunciato la sua partecipazione alla 2025 BIO CEO & Investor Conference.
Il Fondatore, Presidente e CEO dell'azienda, Laxminarayan Bhat, Ph.D., sarà parte di una discussione panel intitolata 'Affrontare la Salute Mentale attraverso Nuovi Obiettivi e Progresso nei Punti di Fine'. Il panel è previsto per martedì 11 febbraio 2025, alle 13:00 ET a New York, NY.
La conferenza si svolgerà dal 10 all'11 febbraio 2025, e le parti interessate possono registrarsi per l'evento e pianificare incontri individuali con il team di gestione di Reviva.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), una compañía farmacéutica en una fase avanzada, centrada en desarrollar terapias para enfermedades del sistema nervioso central (CNS), inflamatorias y cardiometabólicas, ha anunciado su participación en la 2025 BIO CEO & Investor Conference.
El fundador, presidente y CEO de la compañía, Laxminarayan Bhat, Ph.D., será parte de una discusión en un panel titulado 'Abordando la Salud Mental a través de Nuevos Objetivos y Progresos en los Puntos Finales'. El panel está programado para el martes 11 de febrero de 2025, a la 1:00 p.m. ET en Nueva York, NY.
La conferencia se llevará a cabo del 10 al 11 de febrero de 2025, y las partes interesadas pueden registrarse para el evento y programar reuniones uno a uno con el equipo de gestión de Reviva.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)는 중추신경계(CNS), 염증 및 심혈관 대사 질환에 대한 치료제를 개발하는 데 집중하는 후기 단계 제약 회사이며, 2025 BIO CEO & Investor Conference에 참가한다고 발표했습니다.
회사의 설립자, 회장 및 CEO인 Laxminarayan Bhat 박사는 '새로운 목표와 임상적 지표를 통한 정신 건강 과제 해결'이라는 제목의 패널 토론에 참여할 예정입니다. 이 패널은 2025년 2월 11일 화요일 오후 1:00 ET에 뉴욕, NY에서 예정되어 있습니다.
회의는 2025년 2월 10일부터 11일까지 열리며, 관심 있는 분들은 행사에 등록하고 Reviva의 관리팀과 일대일 회의를 예약할 수 있습니다.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), une entreprise pharmaceutique en phase avancée axée sur le développement de thérapies pour les maladies du système nerveux central (CNS), inflammatoires et cardiométaboliques, a annoncé sa participation à la 2025 BIO CEO & Investor Conference.
Le fondateur, président et PDG de l'entreprise, Laxminarayan Bhat, Ph.D., participera à une table ronde intitulée 'S'attaquer à la santé mentale grâce à de nouveaux objectifs et progrès des points d'aboutissement'. Ce panel est prévu pour le mardi 11 février 2025, à 13h00 ET à New York, NY.
La conférence se déroulera du 10 au 11 février 2025, et les personnes intéressées peuvent s'inscrire à l'événement et planifier des réunions individuelles avec l'équipe de direction de Reviva.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), ein Unternehmen der späten Phase, das sich auf die Entwicklung von Therapien für Erkrankungen des zentralen Nervensystems (CNS), entzündliche und kardiometabolische Erkrankungen konzentriert, hat seine Teilnahme an der 2025 BIO CEO & Investor Conference angekündigt.
Der Gründer, Präsident und CEO des Unternehmens, Laxminarayan Bhat, Ph.D., wird an einer Podiumsdiskussion mit dem Titel 'Psychische Gesundheit durch neue Ziele und Fortschritte bei Endpunkten angehen' teilnehmen. Die Diskussion ist für Dienstag, den 11. Februar 2025, um 13:00 Uhr ET in New York, NY, geplant.
Die Konferenz findet vom 10. bis 11. Februar 2025 statt, und interessierte Parteien können sich für die Veranstaltung registrieren und Einzelgespräche mit dem Management-Team von Reviva planen.
- None.
- None.
CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY.
2025 BIO CEO & Investor Conference
Panel Title: Tackling Mental Health through New Targets and Endpoints Progress
Date: Tuesday, February 11, 2025
Time: 1:00 p.m. ET
Location: New York, NY
To register for the conference and schedule a one-on-one meeting with Reviva management, please use the link HERE.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals (RVPH) presenting at the 2025 BIO CEO Conference?
What is the topic of RVPH's panel discussion at the 2025 BIO CEO Conference?
What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?
Can investors meet with RVPH management at the 2025 BIO CEO Conference?
What are the dates for the 2025 BIO CEO & Investor Conference where RVPH is presenting?
